Radius Health, Inc. (NASDAQ:RDUS) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research report issued on Tuesday.

Other equities analysts have also issued reports about the company. Jefferies Group LLC decreased their price objective on Radius Health from $40.00 to $34.00 and set a “hold” rating for the company in a research report on Tuesday, May 2nd. Cantor Fitzgerald reiterated a “buy” rating and issued a $65.00 price objective on shares of Radius Health in a research report on Friday, April 28th. Canaccord Genuity reiterated a “buy” rating on shares of Radius Health in a research report on Friday, April 28th. J P Morgan Chase & Co reiterated a “buy” rating on shares of Radius Health in a research report on Saturday, March 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $63.00 price objective on shares of Radius Health in a research report on Monday, May 15th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. Radius Health presently has a consensus rating of “Hold” and an average price target of $56.83.

Radius Health (NASDAQ:RDUS) traded down 3.77% during mid-day trading on Tuesday, hitting $44.90. 771,482 shares of the stock were exchanged. The stock’s market capitalization is $1.95 billion. The firm has a 50-day moving average price of $37.02 and a 200-day moving average price of $40.17. Radius Health has a 12-month low of $31.58 and a 12-month high of $59.88.

Radius Health (NASDAQ:RDUS) last posted its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.18) by $0.14. During the same period in the prior year, the business posted ($0.94) earnings per share. Equities analysts predict that Radius Health will post ($4.42) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Radius Health, Inc. (RDUS) Upgraded to Buy by BidaskClub” was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/06/27/radius-health-inc-rdus-upgraded-to-buy-by-bidaskclub.html.

In other news, major shareholder Growth N. V. Biotech purchased 43,400 shares of Radius Health stock in a transaction on Monday, May 8th. The stock was purchased at an average price of $35.57 per share, with a total value of $1,543,738.00. Following the transaction, the insider now directly owns 4,785,999 shares in the company, valued at approximately $170,237,984.43. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Growth N. V. Biotech purchased 75,000 shares of Radius Health stock in a transaction on Tuesday, May 2nd. The shares were purchased at an average cost of $33.91 per share, with a total value of $2,543,250.00. Following the transaction, the insider now owns 4,765,399 shares in the company, valued at $161,594,680.09. The disclosure for this purchase can be found here. Insiders purchased a total of 498,400 shares of company stock valued at $17,411,288 over the last quarter. 15.00% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in the company. C WorldWide Group Holding A S increased its position in Radius Health by 0.6% in the first quarter. C WorldWide Group Holding A S now owns 7,397 shares of the biopharmaceutical company’s stock worth $286,000 after buying an additional 43 shares during the period. Envestnet Asset Management Inc. increased its position in Radius Health by 1.1% in the first quarter. Envestnet Asset Management Inc. now owns 4,231 shares of the biopharmaceutical company’s stock worth $163,000 after buying an additional 46 shares during the period. Principal Financial Group Inc. increased its position in Radius Health by 3.1% in the first quarter. Principal Financial Group Inc. now owns 5,970 shares of the biopharmaceutical company’s stock worth $231,000 after buying an additional 180 shares during the period. OppenheimerFunds Inc. increased its position in Radius Health by 0.3% in the first quarter. OppenheimerFunds Inc. now owns 301,631 shares of the biopharmaceutical company’s stock worth $11,658,000 after buying an additional 831 shares during the period. Finally, Swiss National Bank increased its position in Radius Health by 2.1% in the first quarter. Swiss National Bank now owns 49,700 shares of the biopharmaceutical company’s stock worth $1,921,000 after buying an additional 1,000 shares during the period.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, abaloparatide for subcutaneous injection, or abaloparatide-SC, has completed Phase III development for potential use in the treatment of women with postmenopausal osteoporosis.

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.